SciELO - Scientific Electronic Library Online

 
vol.79 número7Los registros en el trasplante de córnea: evaluación de resultados 1995-2000Obstrucción del tubo de los dispositivos de drenaje índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Archivos de la Sociedad Española de Oftalmología

versión impresa ISSN 0365-6691

Resumen

GARCIA GARCIA, O; VIDALLER PALACIN, A; MUNOZ SANCHEZ, J  y  ROCA LINARES, G. Granulocyte-apheresis in ocular Behçet’s disease  resistant to medical treatment. Arch Soc Esp Oftalmol [online]. 2004, vol.79, n.7, pp.335-340. ISSN 0365-6691.

Objective: To assess the feasibility of granulocyte apheresis (GCAP) in patients with Ocular Behçet’s Disease (BD) resistant to immunosuppressive therapy (prednisone, cyclosporin, azathyoprine or mycophenolate mofetil). Methods: Prospective observational study of five cases, carried out in a university centre. Four patients were resistant to medical treatment and one refused immunosuppressive drugs. The intervention procedure consisted of an extracorporeal GCAP using a column filled with cellulose acetate beads (Adacolumn, JIMRO, Takasaki, Japan). All patients received underwent a schedule of therapy of five sessions, once a week for five consecutive weeks. Visual acuity (Snellen lines), the degree of intraocular inflammation and doses of immunosuppressive therapy were measured and observed every week. Results: Visual acuity improved in the five cases. Intraocular inflammation was measured and observed in every case, relapses were avoided, and treatment with prednisone was reduced by more than half of the initial dose (average reduction 52.7%, SD 14). Conclusions: GCAP has been shown to be safe and effective as a new therapy in five cases of Ocular Behçet’s Disease refractory to medical treatment. Further research is needed in order to confirm the promising results of these initial investigations.

Palabras clave : Granulocyte-apheresis; Behçet’s disease; immunosuppressants.

        · resumen en Español     · texto en Español

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons